4.8 Article

Targeting LDH enzymes with a stiripentol analog to treat epilepsy

Journal

SCIENCE
Volume 347, Issue 6228, Pages 1362-1367

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaa1299

Keywords

-

Funding

  1. Japan Society for the Promotion of Science [24590114]
  2. Takeda Science Foundation
  3. Ryobi-Teien Memory Foundation
  4. Grants-in-Aid for Scientific Research [25253008, 24590114, 25460825] Funding Source: KAKEN

Ask authors/readers for more resources

Neuronal excitation is regulated by energy metabolism, and drug-resistant epilepsy can be suppressed by special diets. Here, we report that seizures and epileptiform activity are reduced by inhibition of the metabolic pathway via lactate dehydrogenase (LDH), a component of the astrocyte-neuron lactate shuttle. Inhibition of the enzyme LDH hyperpolarized neurons, which was reversed by the downstream metabolite pyruvate. LDH inhibition also suppressed seizures in vivo in a mouse model of epilepsy. We further found that stiripentol, a clinically used antiepileptic drug, is an LDH inhibitor. By modifying its chemical structure, we identified a previously unknown LDH inhibitor, which potently suppressed seizures in vivo. We conclude that LDH inhibitors are a promising new group of antiepileptic drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available